|
1
|
Chang SS, Bochner BH, Chou R, et al:
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American
Urological Association/American Society of Clinical
Oncology/American Society for Radiation Oncology/Society of
Urologic Oncology Clinical Practice Guideline Summary. J Oncol
Pract. 13:621–625. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Li K and Lin T: Chinese Bladder Cancer
Consortium W, et al.Current status of diagnosis and treatment of
bladder cancer in China - Analyses of Chinese Bladder Cancer
Consortium database. Asian J Urol. 2:63–69. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Milbar N, Kates M, Chappidi MR, et al:
Oncological Outcomes of Sequential Intravesical Gemcitabine and
Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bl
cancer (Amsterdam, Netherlands). 3:293–303. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Berg T, Nøttrup TJ and Roed H: Gemcitabine
for recurrent ovarian cancer - a systematic review and
meta-analysis. Gynecol Oncol. 155:530–537. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
DH J: Gemcitabine for the Treatment of
Non-Small-Cell Lung Cancer. Oncology (Williston Park) 15, 2001.
|
|
6
|
Schlack K, Boegemann M, Steinestel J,
Schrader AJ and Krabbe LM: The safety and efficacy of gemcitabine
for the treatment of bladder cancer. Expert Rev Anticancer Ther.
16:255–271. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Binenbaum Y, Na’Ara S and Gil Z:
Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug
Resist Updat. 23:55–68. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dyawanapelly S, Kumar A and Chourasia MK:
Lessons learned from gemcitabine: Impact of therapeutic carrier
systems and gemcitabine’s drug conjugates on cancer therapy. Crit
Rev Ther Drug Carrier Syst. 34:63–69. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jia Y and Xie J: Promising molecular
mechanisms responsible for gemcitabine resistance in cancer. Genes
Dis. 2:299–306. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nakano T, Saiki Y, Kudo C, et al:
Acquisition of chemoresistance to gemcitabine is induced by a
loss-of-function missense mutation of DCK. Biochem Biophys Res
Commun. 464:1084–1089. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kao Y-T, Hsu W-C, Hu H-T, et al:
Involvement of p38 mitogen-activated protein kinase in acquired
gemcitabine-resistant human urothelial carcinoma sublines.
Kaohsiung J Med Sci. 30:323–30. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Seo HK, Ahn K-O, Jung N-R, et al:
Antitumor activity of the c-Myc inhibitor KSI-3716 in
gemcitabine-resistant bladder cancer. Oncotarget. 5:326–37.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nakamura S and Yoshimori T: New insights
into autophagosome-lysosome fusion. J Cell Sci. 130:1209–1216.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Thorburn A, Thamm DH and Gustafson DL:
Autophagy and cancer therapy. Mol Pharmacol. 85:830–8.
2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu S, Xie F, Wang H, Liu Z, Liu X, Sun L
and Niu Z: Ubenimex inhibits cell proliferation, migration and
invasion in renal cell carcinoma: the effect is
autophagy-associated. Oncol Rep. 33:1372–80. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu S, Wang X, Lu J, et al: Ubenimex
enhances the radiosensitivity of renal cell carcinoma cells by
inducing autophagic cell death. Oncol Lett. 12:3403–3410.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang X-L, Zhang H, Yang X-Y, et al:
Activation of a c-Jun N-terminal kinase-mediated autophagy pathway
attenuates the anticancer activity of gemcitabine in human bladder
cancer cells. Anticancer Drugs. 28:596–602. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kou B, Liu W, Xu X, et al: Autophagy
induction enhances tetrandrine-induced apoptosis via the AMPK/mTOR
pathway in human bladder cancer cells. Oncol Rep. 38:3137–3143.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kabeya Y, Mizushima N, Ueno T, et al: LC3,
a mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–8. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Miracco C, Cevenini G, Franchi A, et al:
Beclin 1 and LC3 autophagic gene expression in cutaneous
melanocytic lesions. Hum Pathol. 41:503–12. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yu L, Chen Y and Tooze SA: Autophagy
pathway: Cellular and molecular mechanisms. Autophagy. 14:207–215.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yoshii SR and Mizushima N: Monitoring and
measuring autophagy. Int J Mol Sci. 18:2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xu X-W, Pan C-W, Yang X-M, Zhou L, Zheng
Z-Q and Li D-C: SP1 reduces autophagic flux through activating p62
in gastric cancer cells. Mol Med Rep. 17:4633–4638. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ojha R, Singh SK, Bhattacharyya S, Dhanda
RS, Rakha A, Mandal AK and Jha V: Inhibition of grade dependent
autophagy in urothelial carcinoma increases cell death under
nutritional limiting condition and potentiates the cytotoxicity of
chemotherapeutic agent. J Urol. 191:1889–98. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nie J, Zhao C, Deng L, et al: Efficacy of
traditional Chinese medicine in treating cancer (Review). Biomed
Reports. 4:3–14. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tariq A, Sadia S, Pan K, et al: A
systematic review on ethnomedicines of anti-cancer plants. Phyther
Res. 31:202–264. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Xu G, Feng C, Zhou Y, et al: Bioassay and
ultraperformance liquid chromatography/mass spectrometry guided
isolation of apoptosis-inducing benzophenones and xanthone from the
pericarp of Garcinia yunnanensis Hu. J Agric Food Chem.
56:11144–50. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang A, He W, Shi H, Huang X and Ji G:
Natural compound oblongifolin C inhibits autophagic flux, and
induces apoptosis and mitochondrial dysfunction in human
cholangiocarcinoma QBC939 cells. Mol Med Rep. 14:3179–3183.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kilani RT, Tamimi Y, Karmali S, Mackey J,
Hanel EG, Wong KK and Moore RB: Selective cytotoxicity of
gemcitabine in bladder cancer cell lines. Anticancer Drugs.
13:557–566. 2002.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun L, Lu J, Niu Z, et al: A Potent
Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine
Resistant Bladder Cancer. PLoS One. 10(e0144484)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kirkali Z, Chan T, Manoharan M, et al:
Bladder cancer: Epidemiology, staging and grading, and diagnosis.
In: Urology. vol. 66:pp4–34. 2005.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li W, Li S, Li Y, et al:
Immunofluorescence staining protocols for major autophagy proteins
including LC3, P62, and ULK1 in mammalian cells in response to
normoxia and hypoxia. In: Methods in Molecular Biology. vol. 1854
Humana Press Inc.:pp175–185. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mozes E, Hunya A, Posa A, Penke B and
Datki Z: A novel method for the rapid determination of beta-amyloid
toxicity on acute hippocampal slices using MTT and LDH assays.
Brain Res Bull. 87:521–5. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lao Y, Wan G, Liu Z, et al: The natural
compound oblongifolin C inhibits autophagic flux and enhances
antitumor efficacy of nutrient deprivation. Autophagy. 10:736–749.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Maulucci G, Chiarpotto M, Papi M, Samengo
D, Pani G and Spirito M De: Quantitative analysis of autophagic
flux by confocal pH-imaging of autophagic intermediates. Autophagy.
11:1905–1916. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kroemer G, Mariño G and Levine B:
Autophagy and the Integrated Stress Response. Mol Cell. 40:280–293.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhou S, Zhao L, Kuang M, et al: Autophagy
in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer
Lett. 323:115–27. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Xi G, Hu X, Wu B, Jiang H, Young CYF, Pang
Y and Yuan H: Autophagy inhibition promotes paclitaxel-induced
apoptosis in cancer cells. Cancer Lett. 307:141–8. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q:
Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol
Cancer. 14:2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shi Z, Li C, Zhao S, et al: A systems
biology analysis of autophagy in cancer therapy. Cancer Lett.
337:149–60. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang F, Tian X, Zhang Z, et al:
Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell
chemosensitivity to gemcitabine in human pancreatic cancer cells
via apoptotic and autophagic pathways. Int J Cancer. 142:1938–1951.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sun WL, Chen J, Wang YP and Zheng H:
Autophagy protects breast cancer cells from epirubicin-induced
apoptosis and facilitates epirubicin-resistance development.
Autophagy. 7:1035–1044. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li Y, Xi Z, Chen X, et al: Natural
compound Oblongifolin C confers gemcitabine resistance in
pancreatic cancer by downregulating Src/MAPK/ERK pathways article.
Cell Death Dis. 9(538)2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Takeuchi H, Mmeje CO, Jinesh GG, Taoka R
and Kamat AM: Sequential gemcitabine and tamoxifen treatment
enhances apoptosis and blocks transformation in bladder cancer
cells. Oncol Rep. 34:2738–2744. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chude CI and Amaravadi RK: Targeting
autophagy in cancer: Update on clinical trials and novel
inhibitors. Int J Mol Sci. 18:2017.PubMed/NCBI View Article : Google Scholar
|
